Interim results of motor-symptom endpoints of an ongoing, open-label study of levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations

被引：0
|
作者：
Espay, A. J.
Chatamra, K.
Fernandez, H. H.
Standaert, D. G.
Hauser, R. A.
Benesh, J.
Caras, S. D.
Pritchett, Y. L.
Lenz, R. A.
机构：
来源：
MOVEMENT DISORDERS | 2011年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
375
引用
收藏
页码：S126 / S126
页数：1
相关论文
共 50 条
  • [41] Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model
    Efthymiopoulou, Efthymia
    Antonoglou, Alexandros
    Loupo, Blerta
    Bougea, Anastasia
    ACTA NEUROLOGICA BELGICA, 2023, 123 (02) : 565 - 570
  • [42] Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson's Disease - INSIGHTS Study
    Chaudhuri, K. Ray
    Weintraub, Daniel
    Antonini, Angelo
    Robieson, Weining Z.
    Li, Mei
    Chatamra, Krai
    Benesh, Janet
    Facheris, Maurizio F.
    MOVEMENT DISORDERS, 2018, 33 : S90 - S90
  • [43] Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson's Disease - INSIGHTS Study
    Chaudhuri, K. Ray
    Weintraub, D.
    Antonini, A.
    Robieson, W.
    Li, M.
    Chatamra, K.
    Benesh, J.
    Facheris, M.
    MOVEMENT DISORDERS, 2018, 33 : S198 - S198
  • [44] Rationale and design of an open-label, randomised, 26-week study comparing levodopa-carbidopa intestinal gel to optimized medical treatment on non-motor symptoms in patients with advanced Parkinson's disease - INSIGHTS study
    Chaudhuri, K. R.
    Weintraub, D.
    Antonini, A.
    Robieson, W.
    Li, M.
    Chatamra, K.
    Benesh, J.
    Facheris, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 315 - 315
  • [45] Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson's Disease - INSIGHTS Study
    Chaudhuri, K. Ray
    Weintraub, Daniel
    Antonini, Angelo
    Robieson, Weining
    Li, Mei
    Chatamra, Krai
    Benesh, Janet
    Facheris, Maurizio
    NEUROLOGY, 2018, 90
  • [46] Non-motor Symptoms after Treatment with Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson's Disease: Analysis of the COSMOS Observational Study
    Johansson, A.
    Tomantschger, V.
    Kovacs, N.
    Dulamea, A.
    Sanchez-Solino, O.
    Bergmann, L.
    Parra, J. Carlos
    Fasano, A.
    MOVEMENT DISORDERS, 2020, 35 : S322 - S323
  • [47] Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs
    Palhagen, Sven E.
    Sydow, Olof
    Johansson, Anders
    Nyholm, Dag
    Holmberg, Bjorn
    Widner, Hakan
    Dizdar, Nil
    Linder, Jan
    Hauge, Tove
    Jansson, Rasmus
    Bergmann, Lars
    Kjellander, Susanna
    Marshall, Thomas S.
    PARKINSONISM & RELATED DISORDERS, 2016, 29 : 17 - 23
  • [48] Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson's disease patients
    Karadag, Yesim Sucullu
    Saltoglu, Tugce
    Kucukdagli, Fadime Erdogan
    Ozturk, Omer
    Koseoglu, Tankut
    Altiparmak, Emin
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (01) : 84 - 89
  • [49] Does levodopa-carbidopa intestinal gel in Parkinson's disease patients increase the risk on polyneuropathy?
    Moes, H.
    Drent, M.
    Laar, T.
    MOVEMENT DISORDERS, 2017, 32
  • [50] Subcutaneous Levodopa Infusion for Parkinson's disease Patients with Motor Fluctuations: Open-Label Efficacy Outcomes from the BeyoND study
    Poewe, W.
    Stocchi, F.
    Adar, L.
    Case, R.
    Yardeni, T.
    Espay, A.
    MOVEMENT DISORDERS, 2021, 36 : S191 - S191
12345